Skip to main content

Buddy Creech Archives

Coronavirus ‘crusaders’ spur VUMC research achievements

Dec. 16, 2020—The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.

Read more


VUMC begins study of second COVID-19 vaccine

Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Read more


COVID treatment studied by VUMC gains FDA approval

Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Read more


Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial

Jul. 15, 2020—In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

Read more


Remdesivir helps reduce COVID-19 recovery time: study

Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

Read more


Vanderbilt investigators encouraged by early results of placebo-controlled remdesivir trial

Apr. 29, 2020—A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

Read more


Vaccine Program receives NIH renewal of VTEU

Feb. 5, 2020—The Vanderbilt Vaccine Research Program has received a grant from the NIH to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units.

Read more


Vaccine Program receives NIH renewal of VTEU

Jan. 23, 2020—The Vanderbilt Vaccine Research Program (VVRP) has received a grant from the National Institutes of Health (NIH) to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units (VTEUs).

Read more


Nasal whooping cough vaccine trial underway at Vanderbilt

Jan. 28, 2019—Vanderbilt vaccine researchers are enrolling adult volunteers in a National Institutes of Health (NIH)-sponsored Phase II clinical trial that will study a next generation pertussis vaccine that may protect people from whooping cough.

Read more


Team seeks to identify immune response to influenza

Nov. 1, 2018—Vanderbilt researchers, as part of the International Human Vaccines Project, are searching for the key to lasting protection against influenza by examining naturally protecting cells found in bone marrow.

Read more


Volunteers sought for bird flu vaccine trial

Mar. 15, 2018—Vanderbilt University Medical Center is recruiting volunteers to participate in a national study of an investigational vaccine against the H7N9 influenza virus, also known as “bird flu.”

Read more


Vanderbilt leads international effort to develop universal flu vaccine

Oct. 26, 2017—Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more